Skip to main content

Table 1 Baseline characteristics and 30-day survival of patients with ARDS for the whole cohort and stratified for in three antibiotic regimen

From: Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

 

Overall cohort

Moxifloxacin monotherapy

Moxifloxacin combination therapy

Other antibiotic therapy

P-value

Total number (%)

169 (100)

42 (25)

44 (26)

83 (49)

 

 Survivors 30-days (%)

117 (69)

28 (67)

31 (70)

58 (70)

0.915

 Non-Survivors 30-days (%)

52 (31)

14 (33)

13 (30)

25 (30)

 

Characteristics

 Age yrs. (range/± SD)

43 (18–75)

45 (±13.1)

41 (±12.5)

43 (±14.7)

0.473

 Male gender (%)

98 (58)

31 (74)

25 (57)

42 (51)

0.045

 Female gender (%)

71 (42)

11 (26)

19 (43)

41 (49)

 

 BMI kg/m2 (±SD)

27,65 (±7.3)

30,0 (±8.6)

27,7 (±6.3)

26,4 (±6.7)

0.016

 ECMO-Therapy (%)

51 (30)

19 (45)

13 (30)

19 (23)

0.070

 Dialysis (%)

83 (49)

25 (59)

22 (50)

36 (43)

0.337

 Antibiotics before ICU admission (%)

142 (84)

35 (83)

38 (86)

69 (83)

0.885

 Cardiovascular disease (%)

25 (14)

4 (10)

6 (14)

15 (14)

0.432

 Prior lung disease (%)

20 (12)

4 (10)

7 (16)

9(18)

0.609

 SAPS II (±SD)

46 (±19.5)

47 (±19.2)

40 (±17.7)

49 (±19.5)

0.057

 LIS (±SD)

3,2 (±0.56)

3,1 (±0.54)

3,1 (±0.59)

3,3 (±0.56)

0.187

 SOFA (±SD)

13 (±6.7)

15 (±7.3)

13 (± 5.6)

12 (±4.4)

0.131

 Horowitz-index upon ICU admission (±SD)

152 (±115.7)

135 (±99.5)

221 (±153.0)

124 (±80.4)

0.001

  1. Data are presented as n (%); mean (± SD) or median(range); BMI body-mass-index, ECMO extracorporeal membrane-oxygenation, SAPS II simplified acute physiology score, LIS Lung-Injury-Score, SOFA Sepsis-related organ failure assessment score; Horowitz-Index: paO2/FiO2; p-values were calculated using the Chi-squared test for categorical variables, ANOVA for continuous parametric variables, and the Kruskal-Wallis test for continuous nonparametric variables